PTIX
Protagenic Therapeutics, Inc. NASDAQ Listed Apr 27, 2021$0.36
+0.00%
vs $0.36
Mkt Cap $651.7K
52w Low $0.13
3.8% of range
52w High $6.20
50d MA $0.32
200d MA $0.80
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-1.3x
ROE
114.2%
P/FCF
-0.2x
RSI (14)
65.30
ATR (14)
$0.04
Beta
0.47
50d MA
$0.32
200d MA
$0.80
Avg Volume
9.4K
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
149 Fifth Avenue · New York City, NY 10010 · US
Data updated apr 28, 2026 6:33pm
· Source: financialmodelingprep.com